Trial
NCT03000634
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Arkansas
Collaborators
—
Condition
Multiple Myeloma
Intervention
Elotuzumab
Why stopped
Study was not and will not be initiated due to lack of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-05